Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214187 · ClinicalTrials.gov registry record · Phase 2
Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 8
- Study locations
NCT01214187 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 58 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT01214187, a Phase 2 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.
Conditions Studied
Interventions
- OTHER Oxygen
- DRUG inhaled carbon monoxide
Study Locations (8)
Illinois
- University of Illinois Chicago - Chicago
- University of Chicago - Chicago
California
- University of California San Francisco - San Francisco
Louisiana
- Tulane University - New Orleans
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Columbia University - New York
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214187
The ClinicalTrials.gov registry entry for NCT01214187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Oxygen is the first listed.
NCT01214187 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Illinois, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT01214187 about?
NCT01214187 is a clinical study titled "Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis". The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.
What is the current status of trial NCT01214187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2011-07. Estimated completion is 2015-04.
What conditions does trial NCT01214187 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT01214187?
The interventions under investigation include: Oxygen (OTHER), inhaled carbon monoxide (DRUG).
Who is sponsoring clinical trial NCT01214187?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01214187 being conducted?
This trial has 8 study locations across California, Illinois, Louisiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.